Platinum-based therapies including carboplatin and cisplatin have been the standard treatment of care as a chemotherapy backbone, in many solid tumors, such as in triple-negative and HER2 positive breast cancer [6,7,8]. This evidence concerns the gene ERBB2 and breast carcinoma.